Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CFH-specific CRISPR-CAS9
- Development stage
- Preclinical
- Lead developer
- Loyola University Chicago
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
01
Overview
CFH-specific CRISPR-CAS9 is a gene-editing tool designed to genetically deplete tumor cell-derived complement factor H (CFH). Developed by researchers at Loyola University Chicago, this CRISPR-Cas9 system targets the CFH gene to suppress glioblastoma (GBM) development. In preclinical models, transduction of human glioma cells with lentiviral particles encoding CFH-specific CRISPR-Cas9 successfully depleted CFH, leading to reduced in vitro cell proliferation and significantly increased survival in murine models of glioblastoma.
02
Targets
CFH (Complement factor H)
Beyond the preview
Go deeper on CFH-specific CRISPR-CAS9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CFH-specific CRISPR-CAS9.